

**THE CHALLENGE OF INFRAPOPLITEAL DISEASE:
CHARACTERISTICS,
RESTENOSIS AFTER ENDOVASCULAR REVASCULARIZATION AND
REVIEW OF SEVERAL NEW TECHNOLOGIES**

Mary L. Yost
404-520-6652
THE SAGE GROUP

THE SAGE GROUP, LLC
RESEARCH AND CONSULTING
23 Ridge Rd
Beaufort SC 29907

Copyright Pending
2023

All rights reserved, including the right of reproduction
in whole or in part in any form.

INDEX OF TABLES

Table 1	8.
Summary Comparison of Estimated Total Lesion Revascularization Rate by Device Type	
Table 2	9.
Meta-Analyses Summary Comparison of Total Lesion Revascularization Rate by Device Type	
Table 3	14.
TASC Infrapopliteal Lesion Types and Description	
Table 4	19.
Infrapopliteal Disease Treated with Percutaneous Transluminal Angioplasty Target Lesion Revascularization Rate in Clinical Trials and Registries	
Table 5	20.
Infrapopliteal Disease Treated with Percutaneous Transluminal Angioplasty Heterogeneity of Selected Patient and Lesion Characteristics	
Table 6	21.
Infrapopliteal Disease Treated with Percutaneous Transluminal Angioplasty Pooled Target Lesion Revascularization Rate in Meta-Analyses	
Table 7	22.
Infrapopliteal Disease Treated with Bare Metal Stents Target Lesion Revascularization Rate in Clinical Trials and Registries	
Table 8	23.
Infrapopliteal Disease Treated with Bare Metal Stents Heterogeneity of Selected Patient and Lesion Characteristics	
Table 9	24.
Infrapopliteal Disease Treated with Bare Metal Stents Pooled Target Lesion Revascularization Rate in Meta-Analyses	
Table 10	25.
Infrapopliteal Disease Treated with Coronary Drug-Eluting Stents Target Lesion Revascularization Rate in Clinical Trials and Registries	
Table 11	26.
Infrapopliteal Disease Treated with Coronary Drug-Eluting Stents Heterogeneity of Selected Patient and Lesion Characteristics	
Table 12	27.
Infrapopliteal Disease Treated with Coronary Drug-Eluting Stents Pooled Target Lesion Revascularization Rate in Meta-Analyses	
Table 13	28.
Infrapopliteal Disease Treated with Drug-Coated Balloons Target Lesion Revascularization Rate in Clinical Trials and Registries	

Table 14	30.
Infrapopliteal Disease Treated with Drug-Coated Balloons Heterogeneity of Selected Patient and Lesion Characteristics	
Table 15	31.
Infrapopliteal Disease Treated with Drug-Coated Balloons Pooled Target Lesion Revascularization Rate in Meta-Analyses	
Table 16	36.
Meta-Analyses of Infrapopliteal Disease Treatments Comparison of Pooled Target Lesion Revascularization Rate (TLR) by Device Type	
Table 17	43.
Sirolimus-Coated Balloons Currently Under Investigation for Treatment of Infrapopliteal Disease	
Table 18	49.
Next Generation Bioresorbable Vascular Scaffolds and Associated Clinical Trials for Treatment of Infrapopliteal Disease	

CONTACT INFORMATION

Mary L. Yost
President
Telephone (404) 520-6652
yost@thesagegroup.us